PARP1 and cancer: Breast cancers harboring germline mutations in either BRCA1 or BRCA2 are highly sensitive to PARP inhibitors [244, 245], and thus, inhibiting PARPs has become a therapeutic strategy for targeting BRCA1/2-mutated cancer cells [246].